Bristol-Myers Squibb has selected a third target under its strategic oncology collaboration with CytomX Therapeutics, triggering a $10 million milestone payment.   “Our collaboration with Bristol-Myers Squibb has progressed very well and we are pleased to expand our collaborative work to a third target,” said Sean McCarthy, D.Phil., president and chief executive officer of CytomX. “We look forward to continuing to work closely with the BMS team to advance product candidates into development.” ...